These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563 [TBL] [Abstract][Full Text] [Related]
3. Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB Bouma J; Broekhuis JD; van der Horst C; Kumar P; Ligresti A; van der Stelt M; Heitman LH Biochem Pharmacol; 2023 Dec; 218():115924. PubMed ID: 37972874 [TBL] [Abstract][Full Text] [Related]
4. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee RG Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291 [TBL] [Abstract][Full Text] [Related]
5. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154 [TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991 [TBL] [Abstract][Full Text] [Related]
8. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents. Bi GH; Galaj E; He Y; Xi ZX Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752 [TBL] [Abstract][Full Text] [Related]
9. Similarities and differences upon binding of naturally occurring Δ Raïch I; Rivas-Santisteban R; Lillo A; Lillo J; Reyes-Resina I; Nadal X; Ferreiro-Vera C; de Medina VS; Majellaro M; Sotelo E; Navarro G; Franco R Pharmacol Res; 2021 Dec; 174():105970. PubMed ID: 34758399 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195 [TBL] [Abstract][Full Text] [Related]
11. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363 [TBL] [Abstract][Full Text] [Related]
12. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227 [TBL] [Abstract][Full Text] [Related]
14. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease. Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564 [TBL] [Abstract][Full Text] [Related]
15. Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Straiker A; Dvorakova M; Zimmowitch A; Mackie K Mol Pharmacol; 2018 Jul; 94(1):743-748. PubMed ID: 29669714 [TBL] [Abstract][Full Text] [Related]
16. Cannabigerol Action at Cannabinoid CB Navarro G; Varani K; Reyes-Resina I; Sánchez de Medina V; Rivas-Santisteban R; Sánchez-Carnerero Callado C; Vincenzi F; Casano S; Ferreiro-Vera C; Canela EI; Borea PA; Nadal X; Franco R Front Pharmacol; 2018; 9():632. PubMed ID: 29977202 [TBL] [Abstract][Full Text] [Related]
17. Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors. Yang Y; Vyawahare R; Lewis-Bakker M; Clarke HA; Wong AHC; Kotra LP Molecules; 2020 Jul; 25(15):. PubMed ID: 32751516 [TBL] [Abstract][Full Text] [Related]
18. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. McPartland JM; Duncan M; Di Marzo V; Pertwee RG Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544 [TBL] [Abstract][Full Text] [Related]
19. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957 [TBL] [Abstract][Full Text] [Related]
20. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM Br J Pharmacol; 2015 Oct; 172(20):4790-805. PubMed ID: 26218440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]